Equities analysts expect that Affimed N.V. (NASDAQ:AFMD) will report sales of $970,000.00 for the current fiscal quarter, according to Zacks. Three analysts have made estimates for Affimed N.V.’s earnings. The lowest sales estimate is $530,000.00 and the highest is $1.77 million. Affimed N.V. posted sales of $1.05 million during the same quarter last year, which suggests a negative year over year growth rate of 7.6%. The company is scheduled to report its next earnings report on Wednesday, November 1st.
On average, analysts expect that Affimed N.V. will report full-year sales of $970,000.00 for the current year, with estimates ranging from $1.10 million to $13.00 million. For the next year, analysts anticipate that the business will report sales of $12.18 million per share, with estimates ranging from $2.13 million to $32.00 million. Zacks’ sales averages are a mean average based on a survey of sell-side research firms that cover Affimed N.V..
Affimed N.V. (NASDAQ:AFMD) last released its quarterly earnings data on Thursday, August 3rd. The biopharmaceutical company reported ($0.20) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.22) by $0.02. The firm had revenue of $0.51 million during the quarter, compared to analyst estimates of $1.31 million. Affimed N.V. had a negative return on equity of 73.85% and a negative net margin of 978.31%. The business’s quarterly revenue was down 75.4% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($0.24) earnings per share.
Several research analysts have recently weighed in on AFMD shares. Oppenheimer Holdings, Inc. set a $10.00 target price on Affimed N.V. and gave the stock a “buy” rating in a report on Saturday, April 15th. Zacks Investment Research upgraded Affimed N.V. from a “hold” rating to a “buy” rating and set a $2.75 target price on the stock in a report on Wednesday, April 19th. Jefferies Group LLC lifted their price target on shares of Affimed N.V. to $2.50 and gave the company a “hold” rating in a research report on Wednesday, April 26th. ValuEngine raised shares of Affimed N.V. from a “strong sell” rating to a “sell” rating in a research report on Friday, June 30th. Finally, SunTrust Banks, Inc. assumed coverage on shares of Affimed N.V. in a research report on Thursday, July 13th. They set a “buy” rating and a $7.00 price target on the stock. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and two have given a buy rating to the company’s stock. The company presently has an average rating of “Hold” and a consensus price target of $4.80.
Several hedge funds have recently added to or reduced their stakes in the stock. Creative Planning raised its stake in Affimed N.V. by 7.7% in the second quarter. Creative Planning now owns 70,000 shares of the biopharmaceutical company’s stock valued at $144,000 after buying an additional 5,000 shares during the last quarter. Nationwide Fund Advisors raised its stake in shares of Affimed N.V. by 9,542.0% in the first quarter. Nationwide Fund Advisors now owns 484,027 shares of the biopharmaceutical company’s stock worth $1,113,000 after buying an additional 479,007 shares during the last quarter. Tekla Capital Management LLC raised its stake in shares of Affimed N.V. by 377.7% in the first quarter. Tekla Capital Management LLC now owns 1,405,324 shares of the biopharmaceutical company’s stock worth $3,232,000 after buying an additional 1,111,111 shares during the last quarter. NEA Management Company LLC purchased a new stake in shares of Affimed N.V. during the first quarter worth about $8,944,000. Finally, Wellington Management Group LLP raised its stake in shares of Affimed N.V. by 30.8% in the first quarter. Wellington Management Group LLP now owns 5,413,291 shares of the biopharmaceutical company’s stock worth $12,450,000 after buying an additional 1,274,852 shares during the last quarter. 42.41% of the stock is currently owned by hedge funds and other institutional investors.
Affimed N.V. (NASDAQ AFMD) traded down 2.33% during trading on Friday, hitting $2.10. The stock had a trading volume of 150,411 shares. Affimed N.V. has a 52-week low of $1.65 and a 52-week high of $3.23. The firm’s 50-day moving average price is $2.23 and its 200-day moving average price is $2.23. The company’s market cap is $92.27 million.
Affimed N.V. Company Profile
Affimed N.V. is a clinical-stage biopharmaceutical company focused on discovering and developing cancer immunotherapies. The Company’s product candidates are developed in the field of immuno-oncology, which represents an approach to cancer research that seeks to harness the body’s own immune system to fight tumor cells.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
What are top analysts saying about Affimed N.V.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Affimed N.V. and related companies.